» Articles » PMID: 33720447

An Examination of Telehealth Policy Impacts on Initial Rural Opioid Use Disorder Treatment Patterns During the COVID-19 Pandemic

Overview
Journal J Rural Health
Specialty Public Health
Date 2021 Mar 15
PMID 33720447
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Tracking changes in care utilization of medication for opioid use disorder (MOUD) services before, during, and after COVID-19-associated changes in policy and service delivery in a mixed rural and micropolitan setting.

Methods: Using a retrospective, open-cohort design, we examined visit data of MOUD patients at a family medicine clinic across three identified periods: pre-COVID, COVID transition, and COVID. Outcome measures include the number and type of visits (in-person or telehealth), the number of new patients entering treatment, and the number of urine drug screens performed. Distance from patient residence to clinic was calculated to assess access to care in rural areas. Goodness-of-Fit Chi-Square tests and ANOVAs were used to identify differences between time periods.

Findings: Total MOUD visits increased during COVID (436 pre vs. 581 post, p < 0.001), while overall new patient visits remained constant (33 pre vs. 29 post, p = 0.755). The clinic's overall catchment area increased in size, with new patients coming primarily from rural areas. Length of time between urine drug screens increased (21.1 days pre vs. 43.5 days post, p < 0.001).

Conclusions: The patterns of MOUD care utilization during this period demonstrate the effectiveness of telehealth in this area. Policy changes allowing for MOUD to be delivered via telehealth, waiving the need for in-person initiation of MOUD, and increased Medicaid compensation for MOUD may play a valuable role in improving access to MOUD during the COVID-19 pandemic and beyond.

Citing Articles

Patient Engagement in Providing Telehealth SUD IOP Treatment: A Retrospective Cohort Study.

Contreras-Schwartz J, ONeill C, Threlkeld A, OCallaghan E, Winsberg M Healthcare (Basel). 2025; 12(24.

PMID: 39765981 PMC: 11675410. DOI: 10.3390/healthcare12242554.


Telehealth and disparities in opioid use disorder treatment: Medicaid enrollees versus privately insured individuals.

Allen L, Xu M Health Serv Res. 2024; 60(1):e14414.

PMID: 39654146 PMC: 11782059. DOI: 10.1111/1475-6773.14414.


Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial.

Lapham G, Hyun N, Bobb J, Wartko P, Matthews A, Yu O JAMA Netw Open. 2024; 7(11):e2447447.

PMID: 39576637 PMC: 11584924. DOI: 10.1001/jamanetworkopen.2024.47447.


Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic.

Marshall S, Siebenmorgen L, Youngen K, Borders T, Zaller N J Prim Care Community Health. 2024; 15():21501319241246359.

PMID: 38600789 PMC: 11008087. DOI: 10.1177/21501319241246359.


Rural and urban clinician views on COVID-19's impact on substance use treatment for individuals on community supervision in Kentucky.

Oser C, Rockett M, Otero S, Batty E, Booty M, Gressick R Health Justice. 2024; 12(1):12.

PMID: 38530619 PMC: 10964696. DOI: 10.1186/s40352-024-00266-9.


References
1.
Ostrach B, Buer L, Armbruster S, Brown H, Yochym G, Zaller N . COVID-19 and Rural Harm Reduction Challenges in the US Southern Mountains. J Rural Health. 2020; 37(1):252-255. PMC: 7405265. DOI: 10.1111/jrh.12499. View

2.
Flavin L, Malowney M, Patel N, Alpert M, Cheng E, Noy G . Availability of Buprenorphine Treatment in the 10 States With the Highest Drug Overdose Death Rates in the United States. J Psychiatr Pract. 2020; 26(1):17-22. DOI: 10.1097/PRA.0000000000000437. View

3.
Whitacre B, Wheeler D, Landgraf C . What Can the National Broadband Map Tell Us About the Health Care Connectivity Gap?. J Rural Health. 2016; 33(3):284-289. DOI: 10.1111/jrh.12177. View

4.
Del Pozo B, Beletsky L . No "back to normal" after COVID-19 for our failed drug policies. Int J Drug Policy. 2020; 83:102901. PMC: 7418724. DOI: 10.1016/j.drugpo.2020.102901. View

5.
Harris M, Johnson S, Mackin S, Saitz R, Walley A, Taylor J . Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report. J Addict Med. 2020; 14(4):e136-e138. PMC: 7273942. DOI: 10.1097/ADM.0000000000000682. View